We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

"As Jazz Pharmaceuticals plc, we are a growing, profitable specialty biopharmaceutical company with a diverse portfolio of products in the central nervous system and women's health areas," said Bruce Cozadd, chairman and chief executive officer at Jazz Pharmaceuticals. "We now have a strengthened management team, a broader commercial organization and an efficient platform for further growth, with resources to build our product portfolio and a future pipeline."

Jazz Pharmaceuticals has approximately 430 employees, including a commercial organization focused around four key areas: narcolepsy, severe chronic pain, psychiatry and a diversified portfolio of women's health products. In addition to its headquarters in Dublin, Ireland, the company has offices in Palo Alto, California and Philadelphia, Pennsylvania.